An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants.
An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants.
复制标题
疫苗接种和感染之间的扩展间隔增强了针对SARS-COV-2变体的杂种免疫力。
DOI：
10.1172/jci.insight.165265
复制
发表时间：
2023-03-08
期刊：
影响因子：
8
通讯作者：
Tafesse, Fikadu G.
中科院分区：
文献类型：
--
作者：
Bates, Timothy A.;Leier, Hans C.;McBride, Savannah K.;Schoen, Devin;Lyski, Zoe L.;Lee, David X.;Messer, William B.;Curlin, Marcel E.;Tafesse, Fikadu G.
随着COVID-19大流行的持续，对SARS-CoV-2的长期免疫将在全球范围内变得重要。自2020年9月以来，官方每周病例数从未低于200万，新变种的持续出现为我们的免疫系统和公共卫生创造了一个移动目标。COVID-19免疫力的时间方面，特别是重复接种疫苗和感染，不如短期疫苗有效性那么好理解。在这项研究中，我们探讨了联合疫苗接种和感染的效果，也被称为杂交免疫，其时间对96名卫生保健工作者的队列中产生的抗体的质量和数量。我们在具有混合免疫的那些人中发现了强有力的中和抗体应答;这些混合免疫应答中和了所有变体，包括BA。与接种间隔较短的人相比，接种间隔较长（最长400天）的人的中和滴度显著提高。这些结果表明，抗SARS-CoV-2抗体应答在最后一次抗原暴露后至少400天通过接种疫苗或感染进行初次暴露后经历持续成熟。我们表明，中和抗体反应改善后，第二次加强，更大的效力后，看到延长的间隔。我们的研究结果也可能延伸到加强疫苗剂量，这是未来疫苗接种策略的关键考虑因素。
As the COVID-19 pandemic continues, long-term immunity against SARS-CoV-2 will be important globally. Official weekly cases have not dropped below 2 million since September of 2020, and continued emergence of novel variants has created a moving target for our immune systems and public health alike. The temporal aspects of COVID-19 immunity, particularly from repeated vaccination and infection, are less well understood than short-term vaccine efficacy. In this study, we explored the effect of combined vaccination and infection, also known as hybrid immunity, and the timing thereof on the quality and quantity of antibodies elicited in a cohort of 96 health care workers. We found robust neutralizing antibody responses among those with hybrid immunity; these hybrid immune responses neutralized all variants, including BA.2. Neutralizing titers were significantly improved for those with longer vaccine-infection intervals of up to 400 days compared with those with shorter intervals. These results indicate that anti–SARS-CoV-2 antibody responses undergo continual maturation following primary exposure by either vaccination or infection for at least 400 days after last antigen exposure. We show that neutralizing antibody responses improved upon secondary boosting, with greater potency seen after extended intervals. Our findings may also extend to booster vaccine doses, a critical consideration in future vaccine campaign strategies.
登录
查看更多内容
影响因子：
24.8
作者：
Bates TA;McBride SK;Leier HC;Guzman G;Lyski ZL;Schoen D;Winders B;Lee JY;Lee DX;Messer WB;Curlin ME;Tafesse FG
通讯作者：
Tafesse FG
影响因子：
64.5
作者：
Payne RP;Longet S;Austin JA;Skelly DT;Dejnirattisai W;Adele S;Meardon N;Faustini S;Al-Taei S;Moore SC;Tipton T;Hering LM;Angyal A;Brown R;Nicols AR;Gillson N;Dobson SL;Amini A;Supasa P;Cross A;Bridges-Webb A;Reyes LS;Linder A;Sandhar G;Kilby JA;Tyerman JK;Altmann T;Hornsby H;Whitham R;Phillips E;Malone T;Hargreaves A;Shields A;Saei A;Foulkes S;Stafford L;Johnson S;Wootton DG;Conlon CP;Jeffery K;Matthews PC;Frater J;Deeks AS;Pollard AJ;Brown A;Rowland-Jones SL;Mongkolsapaya J;Barnes E;Hopkins S;Hall V;Dold C;Duncan CJA;Richter A;Carroll M;Screaton G;de Silva TI;Turtle L;Klenerman P;Dunachie S;PITCH Consortium
通讯作者：
PITCH Consortium
DOI：
10.1126/science.abm0620
发表时间：
2022-01-21
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
通讯作者：
--
DOI：
10.1016/j.medj.2022.02.006
发表时间：
2022-04-08
期刊：
Med (New York, N.Y.)
影响因子：
--
作者：
Miyamoto S;Arashiro T;Adachi Y;Moriyama S;Kinoshita H;Kanno T;Saito S;Katano H;Iida S;Ainai A;Kotaki R;Yamada S;Kuroda Y;Yamamoto T;Ishijima K;Park ES;Inoue Y;Kaku Y;Tobiume M;Iwata-Yoshikawa N;Shiwa-Sudo N;Tokunaga K;Ozono S;Hemmi T;Ueno A;Kishida N;Watanabe S;Nojima K;Seki Y;Mizukami T;Hasegawa H;Ebihara H;Maeda K;Fukushi S;Takahashi Y;Suzuki T
通讯作者：
Suzuki T
影响因子：
16.6
作者：
Bates TA;Leier HC;Lyski ZL;McBride SK;Coulter FJ;Weinstein JB;Goodman JR;Lu Z;Siegel SAR;Sullivan P;Strnad M;Brunton AE;Lee DX;Adey AC;Bimber BN;O'Roak BJ;Curlin ME;Messer WB;Tafesse FG
通讯作者：
Tafesse FG